Pharming Group N.V. PHGUF

PHGUF Company Overview

Pharming Group N.V. is a commercial-stage biotechnology company focused on developing and commercializing therapies for rare diseases with significant unmet medical need. The company operates within the biopharmaceutical industry, with a particular emphasis on rare and ultra-rare genetic disorders. Pharming’s core revenue is generated from approved prescription medicines, supported by in-house development capabilities and selective licensing strategies.

The company’s primary products include Ruconest® (conestat alfa), a recombinant human C1 esterase inhibitor used for the treatment of acute hereditary angioedema (HAE) attacks, and Joenja® (leniolisib), an oral small-molecule therapy approved for activated phosphoinositide 3-kinase delta syndrome (APDS). Pharming serves specialist physicians, hospitals, and rare-disease treatment centers, primarily in North America and Europe. Founded in 1988, the company evolved from an early-stage biotech into a revenue-generating rare-disease company following regulatory approvals and the build-out of its commercial infrastructure.